Extra dose from vials of Comirnaty COVID-19 vaccine
EMA’s human medicines committee (CHMP) has recommended updating the product information for Comirnaty to clarify that each vial contains 6 doses of the vaccine.
In order to extract six doses from a single vial, low dead-volume syringes and/or needles should be used. The low dead-volume syringe and needle combination should have a dead volume of no more than 35 microliters. If standard syringes and needles are used, there may not be enough of the vaccine to extract a sixth dose from a vial.
If the amount of vaccine remaining in the vial after the fifth dose cannot provide a full dose (0.3 ml), the healthcare professional must discard the vial and its contents. There should be no pooling from multiple vials to make up a full dose, and any unused vaccine should be discarded 6 hours after dilution. Further information on all the steps for using Comirnaty is available in the updated product information.
Comirnaty is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 16 years and older. It was authorised in the EU on 21 December 2020.
Information for healthcare professionals
- After dilution, it is possible to obtain six doses from a vial if you use low dead-volume (≤35 μL) syringes and/or needles for all doses.
- Discard the vial and its contents if the amount of vaccine left in the vial is not enough for a full sixth dose (0.3 ml).
- Do not pool from multiple vials to make up an extra dose.
- Discard any unused vaccine 6 hours after dilution.
- Read the product information for full instructions.
More about the vaccine
Comirnaty is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 16 years and older.
It contains a molecule called messenger RNA (mRNA) with instructions for producing a protein from SARS-CoV-2, the virus that causes COVID-19. The vaccine works by preparing the body to attack the spike protein on the surface of SARS-CoV-2.
For more information see Comirnaty.
Clinical Research News
Upcoming Clinical Trials
-
NCT04717258Not yet recruitingConditions: Accidental Fall; Quality of Life; Aged
-
NCT04717284Not yet recruitingConditions: Inflammatory Bowel Diseases
-
NCT04717297Not yet recruitingConditions: Medication Non Adherence; Polypharmacy
-
NCT04717336RecruitingConditions: Cardiovascular Disease
-
NCT04717349RecruitingConditions: Disorders of Sex Development (DSD); Pediatric and Adolescent Cancers of the Genital Tract; Reproductive Endocrine Conditions in Puberty; Structural Gynecologic Conditions Including Vulvar and Vaginal Conditions
-
NCT04717362Not yet recruitingConditions: Hypogonadism, Male; Infertility, Male; Testosterone Deficiency
-
NCT04717375Not yet recruitingConditions: Cancer
-
NCT04717388Not yet recruitingConditions: Tinnitus; Epilepsy, Temporal Lobe
-
NCT04717414Not yet recruitingConditions: Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Anemia
-
NCT04717466Not yet recruitingConditions: Psoriasis; Healthy
Recent CRA jobs
-
Associate Sales Consultant - Trauma - Miami-Fort Lauderdale, FL - FYA01765
-
Applications Administrator (CRM)
-
Analytical Specialist - Physical testing
-
Clinical Trial Coord - Client-dedicated
-
Associate Medical Director (Neurology)
-
GSK GICORS CTM
-
Assoc Mgr, Study Start Up
-
Safety Scientist II
-
(Sr) Project Manager - (FSP) Patient Access Programs
-
Logistics and Data Services Intern